Female patients with heart failure with preserved ejection fraction (HFpEF) on the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide saw a greater reduction in bodyweight than male counterparts in the STEP-HFpEF trials, with otherwise similar treatment benefits, according to a secondary analysis of the program.